Brickell Biotech Aces Pivotal Sofpironium Trials In Patients With Excessive Underarm Sweating
Brickell Biotech Inc (NASDAQ:BBI) has announced positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies of…
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance On All Primary And Secondary Endpoints, From Both U.S. Phase 3 Pivotal Clinical Studies Of Sofpironium Bromide Gel, 15% In Primary Axillary Hyperhidrosis Patients
Brickell Biotech, Inc. (“Brickell”) (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the
Looking Into Brickell Biotech’s Return On Capital Employed
Brickell Biotech (NASDAQ:BBI) brought in sales totaling $151.00 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 28.62%, resulting in a loss of $11.58 million.
Brickell Biotech Acquires Rights To Candidate For Autoimmune Diseases
Brickell Biotech Inc (NASDAQ:BBI) has entered into a definitive agreement with Voronoi Inc for exclusive, worldwide rights to therapeutics generated from a proprietary…
Brickell Biotech Q2 EPS $(0.16) Misses $(0.12) Estimate, Sales $151.00K Down From $607.00K YoY
Brickell Biotech (NASDAQ:BBI) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 62.79 percent increase over losses of $(0.43) per share from
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell
• Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.